Study to Compare Effects of Asundexian and Apixaban on Blood Clot Dissolving in Patients with Atrial Fibrillation

What this Trial Is About

Researchers are investigating how a new blood thinner called asundexian affects the bodys natural ability to dissolve blood clots, known as endogenous fibrinolysis, in patients with atrial fibrillation. This study compares asundexian to apixaban, a commonly used anticoagulant, to see which better improves clot breakdown. This linked observational study builds on the main OCEANIC-AF trial, aiming to reduce risks of heart attack and stroke by targeting impaired clot dissolving mechanisms. Participants are already enrolled in the OCEANIC-AF trial and will have four additional blood samples taken to assess clotting status. Blood samples are collected before starting the study drug and then at 3, 6, and 12 months. The study uses specialized tests like the Global Thrombosis Test and Thromboelastography to evaluate platelet activity, clot formation, and fibrinolysis time, along with various blood markers related to thrombosis. During the study, researchers will monitor thrombotic status over 12 months by analyzing these blood samples. Participants will provide informed consent and agree to blood draws at scheduled visits. The main measurement is how well the body dissolves clots, which may help guide future treatments for atrial fibrillation patients with impaired fibrinolysis.

An Investigator-initiated Linked Study to OCEANIC-AF